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70% in 2009. In unadjusted analysis, the cumulative rates of 
all-cause mortality, EC-specific mortality, and cardiac 
mortality were significantly lower in the IMRT vs 3DCRT group 
(all: 52.4% vs 74.5%, p<0.0001; EC: 40.3% vs. 55.6%, 
p<0.0001; and cardiac: 1.6% vs. 5.3%, p=0.0043). However, 
no difference was seen in deaths from pulmonary (0.96% vs. 
1.55%, p=0.419) or other causes (9.6% vs. 12.1%, p=0.204). On 
propensity score-adjusted MVA, IMRT was not associated with 
EC-specific mortality (HR 0.87, 95%CI 0.69-1.06), pulmonary 
(HR 1.04, 95%CI 0.29-3.79) or other cause mortality (HR 0.81, 
95%CI 0.54-1.22) but was significantly associated with lower 
all-cause mortality (HR 0.83, 95%CI 0.70-0.98) and lower 
cardiac mortality (HR 0.35, 95%CI 0.14-0.88). Similar 
associations were seen adjusting for physician experience and 
sensitivity analysis removing hybrid radiation claims.  
Conclusions: In this population-based analysis, IMRT use was 
significantly associated with lower all-cause mortality and 
cardiac mortality in patients with esophageal cancer. 
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Purpose/Objective: Carotid blowout is an uncommon but 
serious complication of salvage reirradiation (Re-RT) for head 
and neck cancers (HNC). We evaluated carotid artery doses in 
high dose regions during CyberKnife-based fractionated 
stereotactic reirradiation (CK-FSRT) of HNC, and correlated 
them to complication risk. 
Materials and Methods: Patients who received CK-FSRT from 
October 2012 to April 2014 were included. Entire course of 
internal or common carotid arteries ipsilateral to the high 
dose region either within or adjacent to the target volume 
was contoured, and doses to these vessels evaluated (Dmax, 
Dmean, D0.2 cc, D0.5cc, D1cc, V25, V30). The clinical course 
including responses and complications were prospectively 
recorded. 
Results: Twenty-two patients received CK-FSRT during this 
period; of these, 13 (11 males, 2 females) with median age 
56 years (range 31-83 years) received reirradiation, either for 
second primary (2) or recurrence (11); dose being 20-37.5 Gy 
in 3-7 fractions (commonest schedule, 30 Gy in 5 fractions). 
The median interval between the two RT courses was 13 
months (range 3.8-47.7 months). All patients had earlier 
received a dose of 64-70 Gy to the Re-RT region. Median 
follow up post CK-FSRT was 9 months (range 2-19 months). 
During this period, one patient developed carotid bleed 7 
months post-Re-RT that was successfully salvaged with 
angioembolization. There were no treatment-related deaths. 
Dose-volumes were noted for 17 vessels in 13 patients where 
carotid Dmax exceeded 24 Gy for the Re-RT course. Median 
integral dose (volume in ml X dose in Gy) to the vessels was 
41.8 ml-Gy (range 22.4-71.6). Median Dmax (range), D0.2cc 
(range) and D1cc (range) were 33.5 Gy (24.1-44.1), 30.6 Gy 
(22.0-37.6), and 20.37 Gy (7.6-37.6), respectively. Median 
V25 and V30 were 1.08 cc (39.7%) and 0.7 cc (29.7%), 
respectively. Median BED3 maximum and for 0.2 cc volume of 
carotid were 100 Gy (55-146 Gy) and 92.3 Gy (39.9-137.3 Gy), 
respectively for the FSRT plan, and median composite BED3 
maximum was 225 Gy (189-252 Gy). Six patients (7 vessels) 
had at least 50% volume within PTV. The patient who 
developed bleeding was a 73-year lady who had earlier 
undergone surgeries for 2 primaries. The first and repeat 
irradiation interval was 47.7 months and the respective dose-
volume parameters for Re-RT (30 Gy in 5 fractions, 
prescribed to 74% isodose) were: Dmax 39.9 Gy, Dmean 36.2 
Gy, BED3 Dmax (FSRT) 146 Gy, composite BED3 Dmax 252 Gy, 
and V30 18.9cc (100%). 
Conclusions: During SBRT Re-RT, it is advisable to keep 
carotid Dmax BED3 (FSRT & composite) below 145 Gy & 220 
Gy, respectively, though several other factors such as 
diabetes, carotid encasement, number of FSRT fractions, 
inter-RT interval & mucosal involvement contribute to risk. 
Evaluation of a larger number of patients with longer follow 
up and more events would help estimate the relationship 
between carotid doses and observed toxicity, which would 
serve as a useful reference to define respective dose 
constraints for Re-RT.   
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The introduction of 3D image guided brachytherapy has been 
instrumental for reaching new knowledge about dose and 
effect in locally advanced cervix cancer treated with 
combined external beam radiotherapy and brachytherapy. 
Previous to the era of 3D image guided brachytherapy, dose 
assessment was mainly based on points for primary tumour 
(point A) and organs at risk (ICRU bladder and rectum points, 
and applicator related vagina points). ICRU rectum point dose 
has been a successful predictor for rectal bleeding - however, 
the point dose assesments associated with tumour, bladder 
and vagina has not been sufficiently specific to result in 
consistent evidence on dose and effect for local control and 
bladder/vaginal morbidity. During the last decade, the GEC 
ESTRO recommendations on contouring, dose reporting, 
applicator reconstruction and imaging for 3D MRI guided 
brachytherapy have spread throughout the world. This has 
significantly moved the field forward, and currently, a vast 
new experience is being built up on dose and effect with 
regard to both tumour control and morbidity. 
As one of the largest clinical initiatives in 3D image guided 
brachytherapy, the GEC ESTRO Gyn network initiated the 
prospective EMBRACE trial in 2008 (International Study of MRI 
guided Brachytherapy in Cervix Cancer) 
(www.embracestudy.dk). EMBRACE comprises 27 key 
international centers who deliver MRI guided brachytherapy 
in locally advanced cervical cancer according to the GEC 
ESTRO recommendations. The aim of the EMBRACE protocol is 
to benchmark MRI guided brachytherapy in a multicenter 
setting within the frame of a prospective observational study 
and to correlate image based DVH parameters for the clinical 
target volume and for organs at risk with outcome. More than 
1200 patients have been enrolled, and accrual will finalize in 
2015. Furthermore, the retrospective retroEMBRACE study 
has enrolled >700 patients treated with image guided 
brachytherapy from 12 international centers 
